linjc16/ctgov huggingface dataset:
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care

Study Overview
=================
Brief Summary
-----------------
The main purpose of this project is to identify the medium-term prognostic factors for patients with Severe Acquired Brain Injuries and evaluate their impact. The secondary aim is to create a system of continuous assessment of the quality of care for each rehabilitation unit.

Detailed Description
-----------------
For each unit involved, it will be collected these data : Structural and organizational data of the Rehabilitation Units for Severe Acquired Brain Injuries; Detailed information on patients upon entering Rehabilitation Units for Severe Acquired Brain Injuries; Detailed information on patients, re-evaluated 4 months after the acute event Statistical models will be implemented, in order to identify prognostic factors that could predict the probability to observe three events, which represent objectives of the rehabilitation process: decannulation, trunk control and total feeding by os. These events should be evaluated four months after the acute episode.

Official Title
-----------------
TIRESIA Project - Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care

Conditions
-----------------
Brain Injuries, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with Serious Acquired Brain Injuries admission to rehabilitation units Exclusion Criteria: - patients admitted more than 14 weeks after the acute event

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries<br>Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tracheostomy tube | Removal of the tracheostomy tube, which is considered successful if the patient is not to be re-cannulated within 7 days | july 2021 - june 2025 | 
| Trunk control | Achievement of trunk control, for which the patient must be able to maintain the sitting position for at least 60 seconds, on a rigid surface, with the lower limbs in support, but without support from the upper limbs and without rear support of the trunk | july 2021 - june 2025 | 
| Total feeeding by os | Oral feeding with sufficient caloric intake | july 2021 - june 2025 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rehabilitation, Brain Injuries
Iron Bioavailability From MyPyramid Menus

Study Overview
=================
Brief Summary
-----------------
This study will measure nonheme iron absorption from each of the 7 daily MyPyramid menus. Such measurements will confirm whether modifications are needed to meet dietary iron recommendations and will provide data useful for validation algorithms to calculate dietary iron bioavailability.

Detailed Description
-----------------
Nonheme iron absorption is measured with 59Fe tracer added to a 1-day menu, with iron retention detected two weeks later in a whole body scintillation counter. Each subject has iron absorption measured from each of 7 1-d menus formulated to meet the US dietary guidelines (MyPyramid menus), with the order of menus randomly assigned. Each subject participates for 14 wk to test all 7 menus.

Official Title
-----------------
Iron Bioavailability From MyPyramid Menus

Conditions
-----------------
Nonheme Iron Absorption

Intervention / Treatment
-----------------
* Behavioral: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women 21 to 50 years old Exclusion Criteria: Anemia, High blood pressure, Disorders affecting iron absorption or retention, Underlying medical conditions, Taking medication other than birth control pills or hormone replacement therapy, Pregnancy, Daily use of analgesics

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MyPyramid Menu Days 1-7<br>Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks | Behavioral: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7<br>* Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nonheme Iron Absorption | Absorption was estimated from whole body retention of a Iron-59 radiotracer, 2 weeks after consuming a menu labeled with the isotope, then normalized to a ferritin of 15 nanogram/milliLiter (ng/mL) | 2 weeks (wks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
iron absorption, iron requirements, dietary guidelines, MyPyramid
Impact of the Coronavirus (COVID-19) on Patients With Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand the impact of COVID-19 on patients with cancer through a survey.

Detailed Description
-----------------
The global spread of coronavirus (COVID-19) is affecting cancer patients and their treatments. Cancer patients are among those at high risk of developing serious illness from an infection because their immune systems are often weakened by cancer and its treatments. Due to the growing coronavirus outbreak, patients clinic visits are being cancelled and many are facing social isolation and strict restrictions on their daily lives. We want to evaluate the impact of the coronavirus on the patient's well-being and their cancer care by assessing the delays in their medical care and any other unmet needs. We have created a survey that is available online for any patient with cancer to fill out voluntarily regarding their experiences to date. The survey is available at: https://stanforduniversity.qualtrics.com/jfe/form/SV_ctKS6ZSMYdEYoXX

Official Title
-----------------
Impact of the Coronavirus (COVID-19) on Patients With Cancer

Conditions
-----------------
Cancer, COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients must be 18 years or older. Patients who opt in to complete the survey. Patients must have the capacity to verbally consent for the interview. Exclusion Criteria: 1.Patients who under the age of 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who fill out the survey and participate in the semi-structured interviews. | We will track the number of participants who fill out the survey for the 12 month duration of the study and the number of participants who participate in the semi-structured telephone interviews. | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus, COVID-19, Cancer, Life Change Events
Is There a Worse Outcome When the Systolic Blood Pressure is Lower Than Heart Rate in Those Adult Trauma Patients With Isolated Head/Neck Injury

Study Overview
=================
Brief Summary
-----------------
A systolic blood pressure (SBP) lower than the heart rate (HR) could indicate a poor condition in trauma patients. In such scenarios, the reversed shock index (RSI) is <1, as calculated by the SBP divided by the HR. This study aimed to clarify whether RSI could be used to identify high-risk adult patients with isolated traumatic brain injury (TBI).

Official Title
-----------------
Is There a Worse Outcome When the Systolic Blood Pressure is Lower Than Heart Rate in Those Adult Trauma Patients With Isolated Head/Neck Injury

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Other: reversed shock index < 1
* Other: reversed shock index ≥ 1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients having isolated TBI with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included Exclusion Criteria: Patients with incomplete registered data were also excluded

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| isolated traumatic brain injury<br>Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1. | Other: reversed shock index < 1<br>* Among patients with isolated TBI, those with an RSI < 1 had higher mortality<br>Other: reversed shock index ≥ 1<br>* Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in-hospital mortality | To measure the outcome of patients. | up to 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mortality, systolic blood pressure, reversed shock index, traumatic brain injury
A Study to Determine the Role of Physician Gestalt in Predicting COVID-19 in Patients

Study Overview
=================
Brief Summary
-----------------
THIS IS A PROSPECTIVE OBSERVATIONAL STUDY TO DETERMINE THE ROLE OF PHYSICIAN GESTALT IN CLINICAL PREDICTION OF COVID 19.

Detailed Description
-----------------
Among patients attending the Emergency Department, prompt identification of possible cases of COVID 19 is important to avoid the spread. An immediate clinical diagnosis is important for point of care decision making on choice of treatment facility as well as for triaging, testing and to quarantine patients admitted to the hospital from emergency room. Hence this study attempts to find out the role of physician gestalt in early diagnosis and differentiation of COVID 19.

Official Title
-----------------
A Prospective Observational Study to Determine the Role of Physician Gestalt in Clinical Prediction of COVID-19

Conditions
-----------------
All Patients Undergoing COVID 19 Specific Testing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients presenting to ED, who undergo COVID 19 specific testing. Exclusion Criteria: Patients with active COVID 19 disease diagnosed outside All brought dead cases. All patients not consenting to take part in the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity, specificity, positive and negative likelihood ratio of physician gestalt in diagnosis of COVID 19 in patients presenting to ED who are being sent for COVID 19 specific testing. |  | march 2021- september 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity, specificity, positive and negative likelihood ratio of clinical and epidemiological variables in patients presenting to ED who are being sent for COVID 19 specific testing. |  | march 2021- september 2022 |
Prevention of Falls in Older Adults by Specific and Progressive Balance Training

Study Overview
=================
Brief Summary
-----------------
Three months of balance training with follow-up 6 and 12 months thereafter.

Official Title
-----------------
Prevention of Falls in Older Adults by Specific and Progressive Balance Training

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Other: Specific and progressive balance training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 60 years with either osteoporosis or Parkinsons disease Exclusion Criteria: under 60 years

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: One intervention group receiving Specific and progressive balance training One control group
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Intervention<br>Participants in the intervention group receive balance training during 3 months 3 times per week | Other: Specific and progressive balance training<br>* Specific and progressive balance training for the intervention group<br>|
| No Intervention: Control<br>Care as usual | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Balance performance - one leg stand | One leg stand during 30 seconds | up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fear of falling FES-I | Questionnaire measuring fear of falling | up to 24 months | 
| Health related quality of life - SF-36 | Questionnaire measuring health related quality of life | up to 24 months |
Biomarkers for the Detection of Lymphatic Insufficiency

Study Overview
=================
Brief Summary
-----------------
Acquired lymphedema is a disease that causes chronic swelling of the limb(s). It is frequently under-recognized or misdiagnosed. This study is designed to lead to the development of an accurate, noninvasive, blood test to allow testing for lymphedema. This approach is particularly useful to investigate relative responses to treatment interventions.

Detailed Description
-----------------
The validation of a sensitive and specific biomarker assay for human acquired lymphatic vascular insufficiency would represent a highly significant development for the patient community. Accurate bioassay for the presence of lymphatic vascular insufficiency should help to pave the road for future human clinical trials of experimental drugs and therapies designed to treat human lymphatic diseases. Molecular profiling will be performed in human tissues (skin) obtained by biopsy. The insights gained from these initial analyses will determine the targets for assay in human body fluids (blood).

Official Title
-----------------
Biomarkers for the Detection of Lymphatic Insufficiency

Conditions
-----------------
Lymphedema

Intervention / Treatment
-----------------
* Procedure: phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria For lymphedema participants: clinical diagnosis of lymphedema of at least 6 months' duration Control participants: no evidence of lymphedema Exclusion Criteria For lymphedema participants: active cancer infection bleeding tendency active coronary artery disease congestive heart failure history of stroke or transient ischemic attack (TIA) uncontrolled hypertension renal insufficiency (serum creatinine > 1.1) active inflammatory or autoimmune disease (other than lymphedema) For control participants: lymph node dissection radiation therapy active inflammatory disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort with lymphedema<br>Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma. | Procedure: phlebotomy<br>* phlebotomy for collection of plasma and serum,  30 cc<br>* Other names: venipuncture;|
| Cohort without lymphedema<br>Healthy volunteers; will have phlebotomy for serum and plasma. | Procedure: phlebotomy<br>* phlebotomy for collection of plasma and serum,  30 cc<br>* Other names: venipuncture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarkers for the Detection of Lymphatic Vascular Insufficiency |  | one year |
Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.

Official Title
-----------------
Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IBD patients diagnosed by endoscopy. Male and female gender. Disease activity proven clinically and endoscopy . Assiut university hospital patients Exclusion Criteria: Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD patients

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| test the sensitivity and specificity of using NGAL in diagnosis of IBD | test the sensitivity and specificity of using NGAL in diagnosis of IBD | One year |
Evaluation of Dorsal Visual Stream in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Schizophrenia patients in comparing to normal controls show decreased ability to identify objects with decreased level of fragmentation, a task that is associated with magnocellular pathway function.

Official Title
-----------------
Evaluation of Dorsal Visual Stream in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schizophrenia Exclusion Criteria: Ophthalomological or Neurological problems Left handed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, Cognitive deficites, Degraded objects, Magnocellular pathway
Revascularization Strategies for STEMI; The CMR Endpoint Study

Study Overview
=================
Brief Summary
-----------------
Revascularization strategies for ST elevation myocardial infarction (STEMI) study (ASSIST-CMR) will compare the effects of two revascularization strategies [same sitting multivessel primary PCI (SS-PCI) and culprit vessel only primary PCI (IRA-PCI)] on myocardial infarct size (MIS) as determined by cardiac magnetic resonance (CMR) imaging in patients presenting with STEMI and multivessel disease (MVD).

Official Title
-----------------
Revascularization Strategies for ST Elevation Myocardial Infarction; The Cardiac Magnetic Resonance Endpoint Study

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Procedure: IRA-PCI
* Procedure: SS-PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High risk ST elevation myocardial infarction evidenced by: ≥2 mm ST elevation in 2 anterior or lateral leads; or ≥2 mm ST elevation in 2 inferior coupled with ST depression in 2 contiguous anterior leads for a total ST deviation of ≥8 mm; or New left bundle branch block with at least 1 mm concordant ST elevation. Multivessel CAD as evidenced by ≥1 significant (≥70% by visual assessment or FFR<0.80 for 50-70% stenosis) stenosis in non-IRA. Successful IRA-PCI with <10% residual angiographic stenosis and TIMI III flow. Written informed consent. Exclusion Criteria: Age ≤ 18 years. Prior coronary artery bypass graft (CABG) surgery. Administration of thrombolytic therapy. Non-IRA stenosis is a chronic total occlusion or located in left main artery. Hemodynamic instability evidenced by BP<90 mmHg, Killip class ≥2, need for inotropes/vasopressors. Known renal insufficiency (estimated GFR < 50ml/min). Contraindication to CMR.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SS-PCI<br>Same sitting multivessel PCI as an adjunct to primary PCI | Procedure: SS-PCI<br>* Same sitting multivessel PCI as an adjunct to primary PCI<br>|
| Active Comparator: IRA-PCI<br>IRA only PCI with planned staging for non-IRA lesions | Procedure: IRA-PCI<br>* IRA only PCI at the time of Primary PCI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infarct size by CMR |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE rate | MACE rate at 12 months | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stent, Myocardial Infarction, Coronary Intervention